Evidence map›Paper›PMID 35832562›Full record

ArticleFrontiers in oncology2022

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With

Liya Ma, Bin Liang, Huixian Hu, Wenli Yang, Shengyun Lin, Lihong Cao, Kongfei Li, Yuemin Kuang, Lihong Shou, Weimei Jin and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. JCO precision oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 18 institutions in 1 country.

Liya MaDepartment of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Bin LiangDepartment of Hematology, The First Affiliated Hospital of Wenzhou University, Wenzhou, China.
Huixian HuDepartment of Hematology, Jinhua Central Hospital, Jinhua, China.
Wenli YangDepartment of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Shengyun LinDepartment of Hematology, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China.
Lihong CaoDepartment of Hematology, Shulan Hospital of Zhejiang Province, Hangzhou, China.
Kongfei LiDepartment of Hematology, Ningbo Yinzhou People's Hospital, Ningbo, China.
Yuemin KuangDepartment of Hematology, Jinhua People's Hospital, Jinhua, China.
Lihong ShouDepartment of Hematology, Huzhou Central Hospital, Huzhou, China.
Weimei JinDepartment of Hematology, Lishui People's Hospital, Lishui, China.
Jianping LanDepartment of Hematology, Zhejiang Provincial People's Hospital, Hangzhou, China.
Xingnong YeDepartment of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Jing LeDepartment of Hematology, Ningbo Lihuili Hospital, Ningbo, China.
Huyi LeiDepartment of Hematology, The Affiliated Hospital of Shaoxing University of Arts and Sciences, Shaoxing, China.
Jiaping FuDepartment of Hematology, Shaoxing People's Hospital, Shaoxing, China.
Ying LinDepartment of Hematology, The Second Affiliated Hospital of Wenzhou University, Wenzhou, China.
Wenhua JiangDepartment of Hematology, Taizhou First People's Hospital, Taizhou, China.
Zhiying ZhengDepartment of Hematology, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China.
Songfu JiangDepartment of Hematology, The First Affiliated Hospital of Wenzhou University, Wenzhou, China.
Lijuan FuDepartment of Hematology, Xinhua Hospital of Zhejiang Province, Hangzhou, China.
Chuanyong SuDepartment of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, China.
XiuFeng YinDepartment of Hematology, The Affiliated Shaoyifu Hospital of Zhejiang University, Hangzhou, China.
Lixia LiuDepartment of Medical Affairs, Acornmed Biotechnology Co., Ltd., Tianjin, China.
Jiayue QinDepartment of Medical Affairs, Acornmed Biotechnology Co., Ltd., Tianjin, China.
Jie JinDepartment of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
Shenxian QianDepartment of Hematology, Hangzhou First People's Hospital, Hangzhou, China.
Guifang OuyangDepartment of Hematology, Ningbo First Hospital, Ningbo, China.
Hongyan TongDepartment of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou, China.
First Affiliated Hospital Zhejiang University · CNZhejiang Provincial Hospital of TCM · CNZhejiang University · CNFirst Affiliated Hospital of Wenzhou Medical University · CNHangzhou First People's Hospital · CNHuzhou Central Hospital · CNJinhua Academy of Agricultural Sciences · CNJinhua Central Hospital · CNLishui City People's Hospital · CNNingbo First Hospital · CNNingbo Medical Center Lihuili Hospital · CNShaoxing People's Hospital · CNShaoxing University · CNTaizhou First People's Hospital · CNTongde Hospital of Zhejiang Province · CNWenzhou Medical University · CNWenzhou University · CNZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outcomes of myelodysplastic syndrome (MDS) patients with

Indexed as

EZH2Myelodysplastic syndrome (MDS)prognostic scoring modelRasRUNX1SF3B1 mutation

Identifiers

PMID35832562
PMCPMC9271788
OpenAlexW4283592606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.